Francesca Romana Mauro is an expert in Hematology at Sapienza University of Rome (Italy). As of September 2026, ScienceLeadR ranks Francesca Romana Mauro in the top 1% of experts worldwide for Leukemia and Lymphoproliferative Disorders. Francesca Romana Mauro has authored 346 publications, the most recent in 2026, and is an investigator in 8 clinical trials, 1 of them ongoing. SLR score: 1,267 (community average: 125). How the SLR is computed.

LeadR Profile

Francesca Romana Mauro Sapienza University of Rome Italy
1 267 ScienceLeadR Reputation 1267
Network Map

Hematology

Subspecialties: Oncology - Immunology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1985 - 2026

Source: PubMed

Sapienza University of Rome

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 346

Citations

Citations: 7 390 1st author: 49 Last author: 22 Unique author: 3


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Real-World Determinants of Treatment Selection in Frontline Chronic Lymphocytic Leukemia: The FIRST-CLL Study.
PMID 42747083 — hematology, leukemia, lymphocytic, chronic, b-cell, leukemia, leukemia, lymphoid, therapeutics
Hematol Oncol20260
Organizational impacts of fixed-duration therapies for the management of patients with chronic lymphocytic leukemia in Italy.
PMID 42082998 — leukemia, lymphocytic, chronic, b-cell, leukemia, leukemia, lymphoid, rituximab, therapeutics
BMC Health Serv Res20260
Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE Study.
PMID 41899601 — comorbidity, maintenance, drug tapering
Cancers (Basel)20260
Beyond mechanisms: toward patient-centered choices in BTKi-venetoclax fixed-duration therapy for CLL.
PMID 41876726 — leukemia, therapeutics
Leukemia20260
Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi.
PMID 41806221 — cells, vaccines, incidence, hodgkin disease, pre-exposure prophylaxis, lymphoma, vaccination, covid-19, lymphoma, non-hodgkin, lymphoproliferative disorders, b-lymphocytes
Br J Haematol20260

Clinical Studies 8

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2 Study Director: 2

By phase:

Phase 2 5
N/A 2
Phase 1/Phase 2 1

By status:

Completed 6
Active not recruiting 2

By type:

Interventional 6
Observational 2

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 0
multicentricup10 8

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Acalabrutinib Real World Italian obSErvational Study ARISE
NCT06205498 — cells, data collection, leukemia, lymphocytic, chronic, b-cell, leukemia, leukemia, lymphoid, therapeutics, b-lymphocytes
N/AActive not recruiting2023

LeadR Networks

Main global connection map